ALK Shifts R&D Leadership to Advance Allergy+ Strategy
Event summary
- Henriette Mersebach steps down as ALK’s head of R&D on February 23, 2026.
- ALK seeks new R&D leader with a different profile to drive innovation under the Allergy+ strategy.
- Henrik Jacobi, former head of R&D, appointed as special advisor to the CEO.
- All ongoing clinical development programs will continue unchanged.
The big picture
ALK’s leadership change reflects a strategic pivot to enhance its innovation model, aligning with broader industry trends toward diversified allergy therapies. The move underscores the importance of governance shifts in driving long-term growth, particularly in a competitive pharmaceutical landscape where regulatory approvals and pipeline advancements are critical.
What we're watching
- Leadership Transition
- How the new R&D head’s profile will impact ALK’s innovation efforts and Allergy+ strategy execution.
- Strategic Realignment
- Whether ALK can successfully balance core-business growth with expansion into adjacent allergy therapy areas.
- Pipeline Continuity
- The pace at which ALK advances its internal pipeline and partnerships under the new leadership.
Related topics